VABOMERE 1 G — DIN 02554151
MEROPENEM (MEROPENEM TRIHYDRATE) : 1 G VABORBACTAM : 1 G · XEDITON PHARMACEUTICALS INC · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is VABOMERE?
VABOMERE 1 G contains MEROPENEM (MEROPENEM TRIHYDRATE) : 1 G VABORBACTAM : 1 G. It is listed in the Health Canada Drug Product Database under DIN 02554151, held by XEDITON PHARMACEUTICALS INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 30-Jun-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is VABOMERE used for?
VABOMERE (meropenem and vaborbactam) is indicated in adults for the treatment of infections known or suspected to be caused by carbapenem-resistant, vaborbactam/meropenem-susceptible Gram-negative bacteria, including Complicated urinary tract infections (cUTI) including pyelonephritis, Complicated intra-abdominal infection (cIAI), Hospital acquired pneumonia (HAP) including ventilator associated pneumonia (VAP), Bacteremia that occurs in association with (or is suspected to be associated with) any of the infections listed above, and Other infections with limited treatment options. Gram-negative organisms include Enterobacterales, such as Enterobacter cloacae, Escherichia coli, and Klebsiella pneumoniae.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Meropenem And Vaborbactam cost around the world?
Meropenem And Vaborbactam is listed on 9 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| Greece | producer price (ex-factory) | 32 | 32 |
| Saudi Arabia | public | 15 | 19 |
| Italy | ex-factory (classe H) | 15 | 18 |
| South Africa | single exit price | 14 | 15 |
| Czechia | max producer price (ex-factory) | 8 | 14 |
| Romania | max producer price | 11 | 12 |
| Bahrain | retail (max) | 2 | 3 |
| United Kingdom | hospital | 3 | 3 |
| Iceland | max wholesale | 2 | 3 |
119 pack listings across 102 brand entries and 9 price bases, refreshed 03 Sep 2026. Ranges span every Meropenem And Vaborbactam pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 1 G |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | supplied in packs of 6 vials |
| Storage | if stored at room temperature (15 - 30 °C) or 22 hours if stored refrigerated at 2°C to 8°C |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Meropenem And Vaborbactam |
|---|---|
| ATC code | J01DH52 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02554151 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2554151 |
| Brand name | VABOMERE |
| Generic / active ingredient | MEROPENEM (MEROPENEM TRIHYDRATE) : 1 G VABORBACTAM : 1 G |
| Market authorization holder | XEDITON PHARMACEUTICALS INC |
| Health Canada schedule | Prescription |
| ATC code | J01DH52 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01DH |
| Current status | MARKETED |
| Status date | 30-Jun-2025 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Meropenem And Vaborbactam in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by EUGIA PHARMA INC., last seen 21 Aug 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC J01DH
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Meropenem | MEROPENEM FOR INJECTION · MEROPENEM FOR INJECTION SDZ · MEROPENEM FOR INJECTION USP · MEROPENEM FOR INJECTION USP AND SODIUM CHLORIDE INJECTION USP · +3 more | 26 | 15 | Yes |
| Ertapenem | ERTAPENEM FOR INJECTION · INVANZ | 9 | 6 | Yes |
| Imipenem And Cilastatin | IMIPENEM AND CILASTATIN FOR INJECTION · IMIPENEM AND CILASTATIN FOR INJECTION USP · IMIPENEM AND CILASTATIN FOR INJECTION, USP · PRIMAXIN 250 · +4 more | 14 | 2 | Yes |
| Meropenem And Vaborbactam | VABOMERE | 1 | 1 | Yes |
| Doripenem | DORIBAX | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J01D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J01DB | Cefadroxil · Cefalexin · Cefalotin · Cefazolin | 91 | 41 |
| J01DD | Cefixime · Cefotaxime · Cefpodoxime · Ceftazidime · Ceftizoxime · +1 more | 96 | 25 |
| J01DC | Cefaclor · Cefamandole · Cefotetan · Cefoxitin · Cefprozil · +1 more | 135 | 18 |
| J01DE | Cefepime | 10 | 3 |
| J01DF | Aztreonam | 1 | 1 |
| J01DI | Ceftobiprole Medocaril · Ceftolozane And Beta-Lactamase Inhibitor | 2 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is VABOMERE called?
The same molecule, Meropenem And Vaborbactam, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Ultranem | Latin | Saudi Arabia |
| ARCHIFAR | Latin | Czechia |
| MEROLAB | Latin | Bahrain |
| Meropa | Latin | Saudi Arabia |
| MEROPENEM APTAPHARMA | Latin | Czechia |
| MEROPENEM BAUSCH HEALTH | Latin | Czechia |
| MEROPENEM BRADEX | Latin | Czechia |
| MEROPENEM KABI | Latin | Czechia |
| MEROPENEM KABI. | Latin | Saudi Arabia |
| Meropenem Navamedic | Latin | Iceland |
| MEROPENEM OLIKLA | Latin | Czechia |
| MERONEM | Latin | Czechia |
| MEROPENEM AGMED | Latin | Czechia |
| Meropenem SUN | Latin | Iceland |
| MIRAN | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.